Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2021

Open Access 01-12-2021 | Allergic Rhinitis | Research

Translation, adaption and validation of the total nasal symptom score (TNSS) for Lithuanian population

Authors: Laura Tamasauskiene, Edita Gasiuniene, Brigita Sitkauskiene

Published in: Health and Quality of Life Outcomes | Issue 1/2021

Login to get access

Abstract

Background

Allergic rhinitis is one of the most prevalent allergic diseases worldwide which diagnosis is based on typical clinical signs and positive results of allergic tests. Selection and evaluation of treatment is based mainly on subjective symptoms. Objective measurement of patients’ complaints is necessary for proper documentation and follow-up. There are no short simple validated questionnaire assessing nasal symptoms in patients with allergic rhinitis in Lithuania. Total nasal symptoms score (TNSS) is a brief questionnaire which evaluate the severity of main symptoms of allergic rhinitis widely used in different countries. Our aim was to translate the TNSS in the Lithuanian language and to validate it.

Methods

Prospective cross-cultural adaption and validation study was performed. Linguistic validation of TNSS was performed and validity and reliability were assessed. Patients with chronic allergic and non-allergic rhinitis and healthy individuals were included in this study. Patients had to complete translated version of TNSS. Patients with allergic rhinitis additionally were asked to fill Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

Results

Seventy-six individuals were involved into the study: 16 with non-allergic rhinitis (NAR) (21.1%), 49 with allergic rhinitis (AR) (64.5%) and 11 healthy individuals (14.5%). Cronbach’s α was 0.87. TNSS score was significantly higher in patients with NAR and AR compared with healthy individuals (3.56 ± 2.28 vs. 4.28 ± 2.46 vs. 0.27 ± 0.91). Positive significant correlation was found between TNSS score and RQLQ score (rs = 0.77, p < 0.01).

Conclusions

The Lithuanian version of the TNSS proved to be a valid instrument for assessing nasal symptoms in patients with allergic rhinitis.
Literature
1.
go back to reference Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657–65.CrossRef Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657–65.CrossRef
2.
go back to reference Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):1–15.CrossRef Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):1–15.CrossRef
4.
go back to reference Broek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy ClinImmunol. 2010;126(3):466–76.CrossRef Broek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy ClinImmunol. 2010;126(3):466–76.CrossRef
5.
go back to reference Vaitkus S, Padervinskis E, Balsevicius T, Siupsinskiene N, Staikuniene J, Ryskiene S, et al. Translation, cross-cultural adaptation, and validation of the sino-nasal outcome test (SNOT)-22 for Lithuanian patients. Eur Arch Oto-Rhino-Laryngol. 2013;270(6):1843–8.CrossRef Vaitkus S, Padervinskis E, Balsevicius T, Siupsinskiene N, Staikuniene J, Ryskiene S, et al. Translation, cross-cultural adaptation, and validation of the sino-nasal outcome test (SNOT)-22 for Lithuanian patients. Eur Arch Oto-Rhino-Laryngol. 2013;270(6):1843–8.CrossRef
6.
go back to reference Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy ClinImmunol. 1999;104(2):364–9.CrossRef Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy ClinImmunol. 1999;104(2):364–9.CrossRef
7.
go back to reference Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, et al. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59(4):406–14.CrossRef Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, et al. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59(4):406–14.CrossRef
8.
go back to reference Badorrek P, Müller M, Koch W, Hohlfeld JM, Krug N. Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure. Ann Allergy Asthma Immunol. 2017;118:290–7.CrossRef Badorrek P, Müller M, Koch W, Hohlfeld JM, Krug N. Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure. Ann Allergy Asthma Immunol. 2017;118:290–7.CrossRef
9.
go back to reference Garris CP, Stanford RH, Wu WW, Philpot EE. Changes in rhinitis-related quality of life measures are highly correlated with nasal and ocular symptom scores in allergic rhinitis studies. J Allergy Clin Immunol. 2009;123(2):S116.CrossRef Garris CP, Stanford RH, Wu WW, Philpot EE. Changes in rhinitis-related quality of life measures are highly correlated with nasal and ocular symptom scores in allergic rhinitis studies. J Allergy Clin Immunol. 2009;123(2):S116.CrossRef
10.
go back to reference Okubo K, Uchida E, Terahara T, Akiyama K, Kobayashi S, Tanaka Y. Efficacy and safety of the emedastine patch, a novel transdermal drug delivery system for allergic rhinitis: phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group comparative study in patients with seasonal allergic rhinit. AllergolInt. 2018;67(3):371–9. https://doi.org/10.1016/j.alit.2017.12.005.CrossRef Okubo K, Uchida E, Terahara T, Akiyama K, Kobayashi S, Tanaka Y. Efficacy and safety of the emedastine patch, a novel transdermal drug delivery system for allergic rhinitis: phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group comparative study in patients with seasonal allergic rhinit. AllergolInt. 2018;67(3):371–9. https://​doi.​org/​10.​1016/​j.​alit.​2017.​12.​005.CrossRef
12.
go back to reference Yonekura S, Okamoto Y, Sakurai D, Iinuma T, Sakurai T, Yoneda R, Kurita J, Hanazawa TKY. Efficacy of desloratadine and levocetirizine in patients with cedar pollen-induced allergic rhinitis: a randomized, double-blind study. Int Arch Allergy Immunol. 2019;180(4):274–83.CrossRef Yonekura S, Okamoto Y, Sakurai D, Iinuma T, Sakurai T, Yoneda R, Kurita J, Hanazawa TKY. Efficacy of desloratadine and levocetirizine in patients with cedar pollen-induced allergic rhinitis: a randomized, double-blind study. Int Arch Allergy Immunol. 2019;180(4):274–83.CrossRef
13.
go back to reference Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.PubMedPubMedCentral Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.PubMedPubMedCentral
Metadata
Title
Translation, adaption and validation of the total nasal symptom score (TNSS) for Lithuanian population
Authors
Laura Tamasauskiene
Edita Gasiuniene
Brigita Sitkauskiene
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2021
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-01659-8

Other articles of this Issue 1/2021

Health and Quality of Life Outcomes 1/2021 Go to the issue